Tesamorelin in clinical research: visceral fat, liver fat, and limitations

This Research Library page summarizes independently published research on Tesamorelin. For each study, the research design, key finding, and main limitation are described.

Study 1

Level of evidence: Human research - RCT

Topic: Visceral fat in people with HIV receiving antiretroviral therapy.

Key finding: After 26 weeks, visceral fat decreased and some lipid measures improved.

Main limitation: The results apply to a specific patient population and approved use, not to general weight loss.

Source: Original publication via PubMed

Study 2

Level of evidence: Human research - RCT + extension

Topic: Abdominal fat accumulation in people with HIV.

Key finding: An approximately 18% reduction in visceral fat and an improvement in body-image distress were reported.

Main limitation: Indication- and population-specific; some effects disappeared after discontinuation.

Source: Original publication via PubMed

Study 3

Level of evidence: Human research - RCT

Topic: Visceral and hepatic fat in HIV-infected patients with abdominal fat accumulation.

Key finding: The study reported reductions in visceral fat and liver fat.

Main limitation: Small, selected clinical population; no evidence for use outside this context.

Source: Original publication via PubMed

Scientific scope: Research on a molecule, research model, or pharmaceutical formulation does not constitute evidence of the efficacy, safety, purity, or suitability of a commercial Peptidera product. This page does not provide treatment or usage advice.

Header image: illustrative visualization, not a research result.